Prodrugs of 5‐Aminolevullinic Acid for Photodynamic Therapy

Abstract— The use of 5‐aminolevulinic acid (ALA) as a protoporphyrin IX (PpIX) precursor for photodynamic therapy (PDT) became very popular in a short time. However, despite its advantages, ALA also has a drawback; it shows a poor ability to diffuse through biological membranes because of its low Iipophilicity. As a consequence, a high dose of ALA must be administered in order to increase PpIX in the afflicted tissue at a level sufficient for PDT. A possible solution to this problem is the use of derivatives of ALA. ALA prodrugs are expected to have better diffusing properties as a result of their enhanced Jipophilicity and are converted into the parent ALA after enzymatic hydrolysis. In this report, results are presented of the synthesis of a number of ALA derivatives. The ALA prodmgs were investigated regarding the optimum conditions for cell penetration and PPIX formation in an in vitro cellular test system. It is shown that several prod· rugs do indeed enhance the amount of accumulated PPIX considerably as compared to ALA. Finally, the most promising prodrugs were tested in an animal model and showed increased PPIX formation under these conditionsas well.

[1]  W. J. Irwin,et al.  The hydrolysis of azidoprofen esters: A model for a soft anti-inflammatory drug for topical application , 1993 .

[2]  C. A. James,et al.  Ethoxyresorufin-O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with a fluorescence multiwell plate reader. , 1993, Analytical biochemistry.

[3]  S. Anwar,et al.  Synthesis of α-aminoketones via selective reduction of acyl cyanides , 1984 .

[4]  G. Trapani,et al.  In vitro evaluation of N-acyllactam esters of indomethacin as dermal prodrugs , 1995 .

[5]  A. Vercesi,et al.  Damage to rat liver mitochondria promoted by delta-aminolevulinic acid-generated reactive oxygen species: connections with acute intermittent porphyria and lead-poisoning. , 1991, Biochimica et biophysica acta.

[6]  N. Brown,et al.  Kinetics of endogenous protoporphyrin IX induction by aminolevulinic acid: preliminary studies in the bladder. , 1994, The Journal of urology.

[7]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[8]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[9]  H. Kerl,et al.  Photodynamic therapy in patient with xeroderma pigmentosum , 1991, The Lancet.

[10]  A. Batlle,et al.  Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis. , 1993, Journal of photochemistry and photobiology. B, Biology.

[11]  R. Guy,et al.  PERCUTANEOUS PENETRATION ENHANCEMENT: PHYSICOCHEMICAL CONSIDERATIONS AND IMPLICATIONS FOR PRODRUG DESIGN* , 2001 .

[12]  J. Robinson Prodrugs: Topical and Ocular Drug Delivery , 1993 .